Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 8c
November 3, 2016 4:57 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.51), $0.08 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $2.2 million.
Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, We have continued our momentum with a strong quarter, which included the completion of a successful... More
